Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Averting inflammation by targeting the cytokine environment.
Fat-soluble vitamins as disease modulators in multiple sclerosis.
Fingolimod Modulates Peripheral Effector and Regulatory T Cells in MS Patients.
Interleukin-17- and interleukin-22-secreting myelin-specific CD4(+) T cells resistant to corticoids are related with active brain lesions in multiple sclerosis patients.
Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF.
Multiple sclerosis patients treated with intramuscular IFN-β-1a autoinjector in a real-world setting: prospective evaluation of treatment persistence, adherence, quality of life and satisfaction.
Teriflunomide (AUBAGIO). Multiple sclerosis: just a metabolite of leflunomide.
Telephone counseling and home telehealth monitoring to improve medication adherence: Results of a pilot trial among individuals with multiple sclerosis.
Freedom from disease activity in multiple sclerosis.
Dynamic Development of Glucocorticoid Resistance during Autoimmune Neuroinflammation.
Longitudinal Penalized Functional Regression for Cognitive Outcomes on Neuronal Tract Measurements.
Anti-aquaporin-4 antibody in Chinese patients with central nervous system inflammatory demyelinating disorders.
Transcript profiling of different types of multiple sclerosis lesions yields FGF1 as a promoter of remyelination.
Melanocortins as Innovative Drugs for Ischemic Diseases and Neurodegenerative Disorders: Established Data and Perspectives.
Safinamide and flecainide protect axons and reduce microglial activation in models of multiple sclerosis.
Treatment of the chronic progressive form of multiple sclerosis with a combination of cyclophosphamide and prednisone.
Afferent visual pathways in multiple sclerosis: a review.
Cannabinoids control spasticity and tremor in a multiple sclerosis model.
Miscellaneous indications for extracorporeal photochemotherapy (ECP).
Multimodal noninvasive and invasive imaging of extracranial venous abnormalities indicative of CCSVI: results of the PREMiSe pilot study.
Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study.
[Neuromyelitis optica in the elderly: An unusual demyelinating disease.]
Deaths and disability from natalizumab are no longer tolerable: No - (they can be avoided).
A Genome-Wide Integrative Genomic Study Localizes Genetic Factors Influencing Antibodies against Epstein-Barr Virus Nuclear Antigen 1 (EBNA-1).
The long-term cost-effectiveness of the use of Functional Electrical Stimulation for the correction of dropped foot due to upper motor neuron lesion.

Pages